CANDITRAL

MANUFACTURER

Glenmark

DISTRIBUTOR

Glenmark

CONTENTS

Itraconazole

Treatment of oropharyngeal & vulvovaginal candidiasis, pityriasis versicolor, dermatophytoses unresponsive to topical treatment, onychomycosis & systemic infections including aspergillosis, blastomycosis, candidiasis, chromoblastomycoccidioidomycosis, cryptococcosis, histoplasmosis, paracoccidioidomycosis, sporotrichosis.

Also used for fungal infection prophylaxis in immunocompromised patients.

Should not be used in patients with the following conditions:

  • Hypersensitivity to itraconazole or other azole antifungals. Patients w/ evidence of ventricular dysfunction (CHF or history of CHF)
  • Concomitant use w/ cisapride, dofetilide, oral midazolam, pimozide, levacetylmethadol (levomethadyl), quinidine, lovastatin, simvastatin or triazolam; ergot alkaloids eg dihydroergotamine, ergometrine (ergonovine), ergotamine & methylergometrine (methylergonovine)
  • Caution for use in patients with w/ risk factors for CHF eg. ischemic & valvular heart disease, significant pulmonary disease, renal failure & other edematous disorders, Hepatic dysfunction.
  • If neuropathy or signs or symptoms of CHF & liver dysfunction occurs, discontinue.
  • If you are planning to be pregnant or think you may be pregnant, discuss the risks and benefits of use with your doctor.Not interchangeable w/ itraconazole oral solution. Achlorhydria may occur.
  • Before breast-feeding, consult your physician.

Nausea, vomiting, diarrhea, abdominal pain, anorexia, edema, fatigue, fever, malaise, rash, pruritus, headache, dizziness, somnolence, decreased libido, HTN, hypokalemia, albuminuria, abnormal hepatic function, impotence.

 

DRUG INTERACTIONS

Taking multiple drugs may affect how medications work and/or cause unwanted side effects. List down all the medications you are taking and inform your physician and pharmacist. Do not take, discontinue, or alter any dose of medications without prior approval of your physician.

Products that may interact with this medication include:

Quinidine, dofeilide, pimozide, cisapride; HMG-CoA reductase inhibitors eg lovastatin & simvastatin; oral midazolam & triazolam; Ca channel blockers eg dihydropyridines (nifedipine, felodipine) & verapamil; antacids; warfarin; antimycobacterial drugs eg rifampicin, rifabutin & INH; nevirapine; oral hypoglycemic drugs; PIs.

  • Taken with food by mouth, immediately after a full meal.
  • Onychomycosis/Tinea Fingernail and Toenail w/ or w/o fingernail involvement
    • 200 mg twice a day for 1 week each month for 2 months (1 wk on & 3 wk off).
  • Dermatomycoses Tinea corporis & cruris
    • 200 mg once daily for 7 days or 100 mg twice a day for 2 days or 100 mg once daily for 15 days.
  • Plantar tinea pedis & palmar tinea manuum
    • 100 mg once daily for 30 days or 200 mg twice a day for 7 days
  • Tinea capitis
    • 200 mg once daily for 2-4 wk.
  • Pityriasis (tinea versicolor)
    • Treatment: 400 mg as single dose or 400 mg/day for 3 days or 200 mg/day for 5-7 days. Prophylaxis: 200 mg twice a day 1 day/month for 6 consecutive months.
  • Seborrheic dermatitis
    • Treatment: 200 mg/day for 7 days.
    • Prophylaxis: 200 mg once daily for 1st 2 days of each month.
  • Vulvovag candidiasis
    • Acute: 200 mg twice a day for 1 day or 200 mg once daily for 3 days.
    • Recurrent: Acute regimen followed by 200 mg once daily on 1st day of menses for 6 cycles. Oral candidiasis 100 mg once daily for 15 days
    • Patients w/ AIDS/neutropenia
    • 200 mg once daily for 15 days.
  • Aspergillosis (pulmonary & extrapulmonary)
    • Usual dose: 200-400 mg daily (200 mg once daily or twice a day) for minimum of 3 months & until resolution of active fungal infection
    • Life-threatening situations: 600 mg daily (200 mg twice a day) for 1st 3 days as loading dose followed by usual dose
  • Histoplasmosis/blastomycosis
    • 200 mg once daily for a min of 3 month & until resolution of active fungal infection. Dose may be increased in 100-mg increments to max of 400 mg daily.
  • Sporotrichosis
    • 200-400 mg daily (200 mg once daily or twice a day) for a minimum of 3 months & until resolution of active fungal infection. Cryptococcosis (other than meningeal)
    • Treatment: 200 mg twice a day. Maintenance: 200 mg twice a day.
  • Cryptococcal meningitis Prophylaxis in AIDS patients
    • 200 mg once daily. Cocciddioidomycosis 200 mg twice a day for 6 wk.
  • Paracoccidioidomycosis
    • 100 mg once daily for 6 mth.
  • Chromomycosis
    • 100-200 mg once daily for 3-6 months. Other systemic mycoses 200 mg once daily or twice a day until resolution of active symptoms
  • Cryptococcal meningitis
  • Lifelong therapy may be indicated.
  • Neutropenia Treatment
    • (empiric): 200 mg twice a day following 14 days of IV treatment until neutropenia resolves.
  • Prophylaxis (primary or secondary): 200 mg daily
  • AIDS Prophylaxis/prevention of fungal infection: 200 mg daily
  • Oculomycoses
    • 200 mg once daily or twice a day until resolution of active fungal infection.
    • Immunosuppressant therapy/chemotherapy/transplant recipients
    • 400 mg until immune system recovery

Related Articles

LESINURAD

Lesinurad suppresses the enzymes uric acid transporter 1 (URAT1) and organic anion carrier 4 (OAT4), which increases uric acid outflow [...]

LEMBOREXANT

Lemborexant is an orexin potent inhibitor that's competitive. It is considered to prevent the attachment of wake-promoting neurotrophins orexin A [...]

INSULIN LISPRO + INSULIN LISPRO PROTAMINE

Insulin lispro is a fast-acting human insulin alternative, whereas insulin lispro protamine is a slow-acting human insulin alternative. They both [...]